PTLF Stock Overview
Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Petlife Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0007 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -85.71% |
| 3 Year Change | -97.50% |
| 5 Year Change | -97.50% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| PTLF | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.1% | 0.7% |
| 1Y | -85.7% | 9.5% | 23.9% |
Return vs Industry: PTLF underperformed the US Pharmaceuticals industry which returned 9.5% over the past year.
Return vs Market: PTLF underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| PTLF volatility | |
|---|---|
| PTLF Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PTLF has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PTLF's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | n/a |
Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company’s principal product is Vitalzul that inhibits blood vessels formation in solid tumors. It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concentrated intravenous and injectable version for direct administration to a tumor.
Petlife Pharmaceuticals, Inc. Fundamentals Summary
| PTLF fundamental statistics | |
|---|---|
| Market cap | US$22.21k |
| Earnings (TTM) | -US$3.71m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs PTLF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PTLF income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$17.92k |
| Gross Profit | -US$17.91k |
| Other Expenses | US$3.69m |
| Earnings | -US$3.71m |
Last Reported Earnings
Feb 28, 2018
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did PTLF perform over the long term?
See historical performance and comparison